Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82
Canaccord Genuity Initiates Coverage On Moderna With Hold Rating, Announces Price Target of $82
Canaccord Genuity以持有評級啓動對Moderna的報道,宣佈目標股價爲82美元
Canaccord Genuity analyst Bill Maughan initiates coverage on Moderna (NASDAQ:MRNA) with a Hold rating and announces Price Target of $82.
Canaccord Genuity分析師比爾·莫恩以持有評級開始對Moderna(納斯達克股票代碼:MRNA)進行報道,並宣佈目標股價爲82美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。